Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.

Clinical pharmacology and therapeutics - 1 Jul 2004

Vianna-Jorge Rosane, Perini Jamila A, Rondinelli Edson, Suarez-Kurtz Guilherme

Abstract excerpt

OBJECTIVE: Cytochrome P450 (CYP) 2C9, the product of the polymorphic gene CYP2C9, provides the major catabolic pathway for several anti-inflammatory drugs, including tenoxicam. Our objectives were (1) to determine the frequency of 2 common CYP2C9 variant alleles (*2 and *3) in the Brazilian population and (2) to evaluate the effects of these polymorphisms on the pharmacokinetics of tenoxicam. METHODS: Polymerase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Area Under Curve
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brazil

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 15229460
DOI: 10.1016/j.clpt.2004.03.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.PMID 15229460Read ↗

Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.Semantic proximity Read ↗

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.Semantic proximity Read ↗

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.Semantic proximity Read ↗

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model.Semantic proximity Read ↗

Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism.Semantic proximity Read ↗

Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.Semantic proximity Read ↗

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.Semantic proximity Read ↗

Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.Semantic proximity Read ↗

CYP2C8 polymorphism among the Portuguese.Semantic proximity Read ↗

Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.Semantic proximity Read ↗

Effect of the CYP2C9*3 allele on lornoxicam metabolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.